Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ADX48621 (Dipraglurant) for levodopa-induced dyskinesia in Parkinson's disease
2010-022517-25Phase 2Completed
- Sponsor
- Addex Therapeutics Ltd
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in levodopa-induced dyskinesia (LID) comparing Dipraglurant with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Feb 2011; status: completed.
02
Drugs
dipraglurant
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on 2010-022517-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022517-25.